Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Danegaptide by Breye Therapeutics for Diabetic Retinopathy: Likelihood of Approval
Danegaptide is under clinical development by Breye Therapeutics and currently in Phase II for Diabetic Retinopathy. According to GlobalData, Phase...
Data Insights
Danegaptide by Breye Therapeutics for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Danegaptide is under clinical development by Breye Therapeutics and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration....